Teva: Study Finds Austedo Provided Improvements In TD-related Movements In Postmenopausal Women

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new efficacy and safety data from a 3-year open-label extension study on Austedo (deutetrabenazine) tablets in postmenopausal women with tardive dyskinesia or TD.

The company will present data at the 2022 American Psychiatric Association (APA) Annual Meeting, held May 21-25 in New Orleans and online June 7-10.

The analysis found Austedo provided improvements in TD-related movements in postmenopausal women. Majority of patients showed improvement across two patient outcome measures, Patient Global Impression of Change, and Clinical Global Impression of Change. AUSTEDO safety findings were consistent with findings from the overall OLE study population (n=337), with no new safety concerns from long-term treatment.

The physical, psychological and social impact of TD was examined in two studies that assessed the burden and stigma of TD, regardless of the underlying condition, from the perspectives of both patients and caregivers in the U.S.

Findings demonstrated that TD has a significant psychological and social impact on patients and the patient experience can provide insight into stigma associated with TD.

According to the Findings, Over half of patients reported often/always feeling psychological impacts of TD, such as low self-esteem, fear of being rejected, being anxious/worried, being embarrassed, and being irritable/frustrated/angry.

Over 90% of patients reported TD impacted physical functioning, with over two-thirds reporting moderate-to-severe impact on 15 of 24 impact measures, including: ability to fall asleep (86.3%), ability to exercise and do household chores (77%, 76.6%), ability to hold items such as glass or fork (76.3%), worry about choking (76.2%), and feeling self-conscious about speech difficulties (74.8%).

Austedo is indicated for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia in adults.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Luxury electric car maker Tesla Inc. has produced more than 3 million vehicles, of which 1 million in Shanghai Gigafactory, according to its founder and Chief Executive Officer Elon Musk. In a tweet on Sunday, Musk said, "Congrats Giga Shanghai on making millionth car! Total Teslas made now over 3M." King's Hawaiian is recalling its Pretzel Slider Buns, Pretzel Hamburger Buns and Pretzel Bites products as they contain one ingredient already recalled by Lyons Magnus, the U.S. Food And Drug Administration said. The Pretzel recall was initiated out of an abundance of caution after one of its supplier Lyons Magnus recently called back various nutritional and beverage products. German consumer goods maker Henkel AG & Co. reported Monday weak profit in its first half amid increasing costs, despite growth in sales. Further, the company maintained its adjusted earnings forecast for fiscal 2022, but raised outlook for organic sales growth.For fiscal 2022, the company continues to expect adjusted earnings per preferred share to decline in the range of 15 percent to 35 percent
Follow RTT